Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan

International Journal of Antimicrobial Agents

Volumn 26, Issue 6, 2005, Pages 463-472

  Hsueh, Po Ren ^a   Chen, Wen Hwei ^a   Luh, Kwen Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antimicrobial resistance; Antimicrobial use; Gram negative bacteria; Nosocomial infection; Taiwan

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG FORMULATION; DRUG USE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; INFECTION RATE; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SEVERE ACUTE RESPIRATORY SYNDROME; STENOTROPHOMONAS MALTOPHILIA; UNIVERSITY HOSPITAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORINS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; LENGTH OF STAY; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; TAIWAN;

EID: 27744532776     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.08.016     Document Type: Article

References (38)

1. L. Archibald, L. Phillips, and D. Monnet Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit Clin Infect Dis 24 1997 211 215
2. R.K. Flamm, M.K. Weaver, and C. Thornsberry Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002 Antimicrob Agents Chemother 48 2004 2431 2436
3. P.R. Rhomberg, R.N. Jones, and H.S. Sader Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres Int J Antimicrob Agents 23 2004 52 59
4. H.S. Sader, D.J. Biedenbach, and R.N. Jones Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48, 440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001) Diagn Microbiol Infect Dis 47 2003 361 364
5. S.K. Fridkin, C.D. Steward, and J.R. Edwards Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals Clin Infect Dis 29 1999 245 252
6. P.R. Hsueh, L.J. Teng, and C.Y. Chen Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan Emerg Infect Dis 8 2002 827 832
7. P.R. Hsueh, M.L. Chen, and C.C. Sun Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999 Emerg Infect Dis 8 2002 63 68
8. P.R. Hsueh, Y.C. Liu, and D. Yang Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan Microb Drug Resist 7 2001 373 382
9. J.A. Karlowsky, M.E. Jones, and C. Thornsberry Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 Antimicrob Agents Chemother 47 2003 1672 1680
10. P. Nordmann, and L. Poirel Emerging carbapenemases in gram-negative aerobes Clin Microbiol Infect 8 2002 321 331
11. J. Van Eldere Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections J Antimicrob Chemother 51 2003 347 352
12. B. Allegranzi, R. Luzzati, and A. Luzzani Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections J Hosp Infect 52 2002 136 140
13. D.N. Fish, S.C. Piscitelli, and L.H. Danziger Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies Pharmacotherapy 15 1995 279 291
14. A.C. Fluit, J. Verhoef, and F.J. Schmitz Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998 Eur J Clin Microbiol Infect Dis 20 2001 617 625
15. Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan Jr JE; Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project; National Nosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001;33:324-30.
16. R. Gaynes The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals Infect Dis Clin North Am 11 1997 757 765
17. C. Gentry, D.J. Flournoy, and R. Reinert Analysis of antimicrobial resistance among gram-negative bacilli and antimicrobial use in intensive care unit patients for 5 years in a Veterans Affairs medical center Am J Infect Control 30 2002 411 416
18. J.M. Loeffler, J. Garbino, and D. Lew Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units Scand J Infect Dis 35 2003 843 850
19. E. Meyer, D. Jonas, and F. Schwab Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI) Infection 31 2003 208 215
20. B. Olson, R.A. Weinstein, and C. Nathan Occult aminoglycoside resistance in Pseudomonas aeruginosa: epidemiology and implications for therapy and control J Infect Dis 152 1985 769 774
21. L.V. Friedrich, R.L. White, and J.A. Bosso Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes Clin Infect Dis 28 1999 1017 1024
22. J. Gulbinovic, K.E. Myrback, and J. Bytautiene Marked differences in antibiotic use and resistance between university hospitals in Vilnius, Lithuania, and Huddinge, Sweden Microb Drug Resist 7 2001 383 389
23. J.S. Garner, W.R. Jarvis, T.G. Emori, T.C. Horan, and J.M. Hughes CDC definitions for nosocomial infections, 1988 Am J Infect Control 16 1988 128 140 [Erratum. Am J Infect Control 1988;16:177]
24. Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs) for Plain Substances. Oslo, Norway: WHO Collaborating Center for Drug Statistics and Methodology; 2001.
25. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility test; Approved Standards, eighth ed. M2-A7. Wayne, PA: NCCLS; 2002.
26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 13th Informational Supplement. M100-S13 (M7). Wayne, PA: NCCLS; 2003.
27. A. Mahamat, J.P. Lavigne, P. Fabbro-Peray, J.M. Kinowski, J.P. Daures, and A. Sotto Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model Clin Microbiol Infect 11 2005 301 306
28. J.M. Lopez-Lozano, D.L. Monnet, and A. Yague Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis Int J Antimicrob Agents 14 2000 21 31
29. C. Bantar, E. Vesco, and C. Heft Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance Antimicrob Agents Chemother 48 2004 392 395
30. C.A. Lesch, G.S. Itokazu, and L.H. Danziger Multi-hospital analysis of antimicrobial usage and resistance trends Diagn Microbiol Infect Dis 41 2001 149 154
31. M.M. Neuhauser, R.A. Weinstein, and R. Rydman Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use JAMA 289 2003 885 888
32. L.B. Rice, E.C. Eckstein, and J. DeVente Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center Clin Infect Dis 23 1996 118 124
33. M.J. Schwaber, S.E. Cosgrove, and H.S. Gold Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens Emerg Infect Dis 10 2004 94 99
34. D.A. Goldmann, and W.C. Huskins Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide Clin Infect Dis 24 Suppl. 1 1997 S139 S145
35. C. MacDougall, J.P. Powell, C.K. Johnson, M.B. Edmond, and R.E. Polk Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals Clin Infect Dis 41 2005 433 440
36. R.L. White, L.V. Friedrich, and L.B. Mihm Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas Clin Infect Dis 31 2000 16 23
37. G.T. Ray, R. Baxter, and G.N. DeLorenze Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa Clin Infect Dis 41 2005 441 449
38. D.K. Warren, and V.J. Fraser Infection control measures to limit antimicrobial resistance Crit Care Med 29 4 Suppl. 2001 N128 N134